Rhythm Pharmaceuticals Inc (RYTM) Stock AnalysisRYTMStock AnalysisRhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rhythm Pharmaceuticals Inc is currently a hold. The current price is $107.17, with a gross margin of 26.52% reported for Q2 2026, which is significantly lower than previous quarters. The forward P/E ratio is not applicable, indicating potential volatility. However, the recent approval of IMCIVREE in Japan could drive future growth, as it opens up a new market for the company. The main risk is the declining gross margin, which has dropped from over 90% in previous quarters to 26.52% in the latest report, indicating potential challenges in maintaining profitability.

4 analysts cover RYTM: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 140.62.